



Takafumi Horii

Head, Japan
Oncology Business Unit

Takafumi Horii (Taka) is a corporate executive with 20 years of extensive business experience at global, leading firms in pharmaceutical, high-tech and IT industries and who has lived and worked in 7 countries., successful in multi-cultural environment with in-depth experiences both in matured and emerging markets. Currently, Taka is Head of Japan Oncology Business Unit at Takeda as a part of Global Oncology Leadership Team, also serving on the Japan Leadership Committee.

He joined Takeda in 2009 in Corporate Strategy & Planning. Since then, he has held roles of increasing responsibility, including Head of Strategic Planning in China, Head of Strategic Project & Planning at North Asia in Tokyo, Head of Strategy & Business Support, Emerging Markets BU in Singapore, President & General Manager in Taiwan and Area Head of Near East, Middle East & Africa in Dubai and plays a critical role during transition and post-merger integration of Takeda's acquisition of Shire PLC (now part of Takeda) in this region. In addition, he served on the Executive Committee of PhRMA Middle East and Africa based in Dubai, as the Standing Director & Market Access Committee Chair at International Research-Based Pharmaceutical Manufacturers Association in Taiwan, and as the Vice Chairperson of Pharmaceuticals and Medical Devices Committee at the Japanese Chamber of Commerce and Industry Taipei to provide industry leadership in each market respectively.

Before joining Takeda, he joined a US-based IT start-up firm (currently a part of SAP Inc.), developed Japanese clients in the healthcare sector as well as in the automotive, electronics and private equity industries where he launched a new business model (SaaS) as part of business model transformation. He was also a global strategic sourcing and supply chain manager at Canon Inc., the global leading manufacturing company with annual sales turnover of USD 40 billion.

Taka holds a BA in Law in Japan and an MBA from the Darden School of Business at the University of Virginia in Virginia, US. In addition, he has completed an Executive Development Program at Tsinghua University, China. He is native in Japanese and fluent in English and Mandarin.



ONCOLOGY